Vellykket registrering
Din registrering er satt på vent
Din konto er aktivert, men fordi vårt system ikke umiddlebart kunne gjenkjenne deg som helsepersonell må det gjøres en manuell sjekk. Du vil motta en e-post med resulatet i løpet av få dager.
I mellomtiden har du tilgang til alle tjenester på portalen.
Eosinophils may play a role in maintaining health by helping:1,2
- to regulate the immune system
- to defend the body from patogens
Elevated eosinophils in severe asthma are associated with:3-5
- eosinophilic inflammation
- airway remodeling
EOSINOPHILS AND NUCALA MODE OF ACTION
*From a historical registry study with 1716 adult patients with severe asthma and available blood eosinophil count who were enrolled in the International Severe Asthma Registry. 83.8% were identified as most likely (grade 3) to have an eosinophilic phenotype.9
Nucala is a humanised IL-5 antagonist monoclonal antibody.6
Interleukin-5 (IL-5) is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils.7
The latest GINA guidelines recommend add-on anti-IL-5/5R treatments for patients with SEA.8
*In patients with severely refractory eosinophilic asthma (adults/adolescents), after a subcutaneously administered dose of 100mg Nucala every 4 weeks for 32 weeks, blood eosinophils were reduced from a geometric mean number of 290 cells/µl at baseline to 40 cells/µl at week 32 (n=182); which is an 84% reduction compared to placebo.6
*COLUMBA was an open-label extension study in patients with severe eosinophilic asthma previously enrolled in the DREAM study. 347 patients received Nucala every 4 weeks, for an average of 3.5 years (maximum 4.5 year). Mean blood eosinophil count was reduced from 240 cells/µL at baseline to 50 cells/µL at Week 4 and remained suppressed throughout the study period.10
SELECTED SAFETY INFORMATION
Warnings/Precautions: Should not be used to treat acute asthma exacerbations. Patients should be instructed to seek medical advice if their asthma remains uncontrolled or worsens after starting treatment. Abrupt discontinuation of corticosteroids after initiation of mepolizumab treatment is not recommended.
Allergic reactions: Acute and delayed systemic reactions, including hypersensitivity reactions, have occurred following administration of mepolizumab. Patients should be instructed to seek medical attention immediately if allergic reactions occur. In the event of a hypersensitivity reaction, appropriate treatment as clinically indicated should be initiated.
Parasitic infections: Pre-existing helminth infections should be treated before starting therapy. If patients become infected whilst receiving treatment with mepolizumab and do not respond to anti-helminth treatment, temporary discontinuation of therapy should be considered.
Adverse reactions: In clinical studies in patients with severe refractory eosinophilic asthma, headache, injection site reactions and back pain were the most commonly reported adverse reactions during treatment.
Need more information?
Abbreviations:
CI, confidence interval; IL, interleukin; SC, subcutaneous; SD, standard deviation.
References:
- Weller PF et al. Nat Rev Immunol. 2017;17(12):746-760.
- Wen T et al. Microbiol Spectr. 2016;4do:10.1128/microbiolspec. MCHD-0020-2015.)
- Buhl R et al. J Allergy Clin Immunol Pract. 2020;8(8):2630-2639.e6.
- Malinovschi A et al. J Allergy Immunol. 2013;132:831-837.
- Peters MC et al. Am J Respir Crit Care Med. 2020;202(7):973-982
- SmPC Nucala
- Trivedi SG et al. Cell Mol Life Sci. 2007;64(10):1269-1280
- Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2022.
- Heaney LG, et al. Chest. 2021;160(3):814-830.
- Khatri S, et al. J Allergy Clin Immunol. 2019;143(5):1742-1751.e7.
© 2023 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.
PM-NO-MPL-WCNT-230030 - September 2023
